Ranibizumab 0.5 mg for diabetic macular edema with bimonthly monitoring after a phase of initial treatment: 18-month, multicenter, phase IIIB RELIGHT study

Ian Pearce, Sanjiv Banerjee, Ben Burton, Usha Chakravarthy, Louise Downey, Richard Gale, Jonathan Gibson, Sergio Pagliarini, Jignesh Patel, Sobha Sivaprasad, Chis Andrews, James Warburton,

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'Ranibizumab 0.5 mg for diabetic macular edema with bimonthly monitoring after a phase of initial treatment: 18-month, multicenter, phase IIIB RELIGHT study'. Together they form a unique fingerprint.

Medicine & Life Sciences